MediWound

Historical price data

MediWound is an Israeli biotech company with a mission to deliver innovative, cost-effective enzymatic solutions for severe burn care and hard-to-heal wounds. Its key achievement is the global regulatory approval and commercialization of NexoBrid, an orphan biologic for burn eschar removal, including recent FDA approval in December 2023. The company's strategy leverages a fully integrated, vertically operational model—spanning R&D, cGMP manufacturing, and targeted commercialization—to advance its core bromelain-based platform into large chronic wound markets, with EscharEx currently in Phase 3 trials.

Proprietary platform based on proteolytic enzymes enriched from the bromelain family, enabling selective enzymatic debridement that targets non-viable tissue while preserving healthy tissue.

In burns, NexoBrid competes primarily with traditional surgical debridement, holding an advantage with its selective, non-surgical approach and orphan drug status. In chronic wounds, EscharEx will face competition from various debridement methods (surgical, autolytic, mechanical, other biologicals), requiring robust data to demonstrate superior efficacy and cost-effectiveness.